News

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

2016-04-19

On April 15th, CFDA announced on internet that anti-infection 1.1 new drug PL-5 of Jiangsu ProteLight Pharma was approved to be in clinical trial, which is the first antimicrobial peptide innovative drug in clinical trial in China. With characters of low toxicity, high efficiency and anti-drug resistant bacteria, PL-5 has a significant advantage of disinfecting “the super bacteria”, which is resistant to traditional antibiotics. Antimicrobial peptide PL-5 being in clinical trial can relieve the suffering of patients with skin infection.

Previous article

CCTV News reported ProteLight

Next article

Our New Technology Got U.S. Invention Patent License

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China